trending Market Intelligence /marketintelligence/en/news-insights/trending/_auIAaPcAIi4Q6BKz8xb1w2 content esgSubNav
In This List

Fennec Pharmaceuticals seeks US FDA approval for hearing loss prevention drug

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Fennec Pharmaceuticals seeks US FDA approval for hearing loss prevention drug

Fennec Pharmaceuticals Inc. has submitted a rolling new drug application to the U.S. Food and Drug Administration seeking approval to market its drug that prevents hearing loss resulting from chemotherapy.

Fennec's Pedmark, a formulation of sodium thiosulfate, deactivates the metabolic consequences of platinum compounds used in chemotherapy and prevents toxicity in the ear that can cause temporary or permanent hearing loss. The drug is under development to treat patients between one month to 18 years of age and has been evaluated in two late-stage trials, COG ACCL0431 and SIOPEL 6.

The FDA previously granted Fennec breakthrough therapy status and fast-track designation for Pedmark. The breakthrough therapy designation will include an accelerated review process, as well as more intensive FDA guidance on an efficient drug development program.

Fennec expects to get approval for Pedmark from the FDA in the second half of 2019 and will also submit a marketing application to the European Medicines Agency. The EMA's Paediatric Committee responsible for children's medicines recently approved a pediatric investigation plan for Pedmark.

Research Triangle Park, N.C.-based Fennec is a biopharmaceutical company that develops product candidates for use in treating cancer in the U.S.